Relmada Therapeutics Inc (RLMD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.77-9.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RLMD
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-6.9) + peer(0.2*0.0) + term(0.0) → -2.4% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 7 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 6, 2026, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the three months ended June 30, 2026. The Company also announced that it would conduct a conference call and audio webcast on Thursday, August 6, 2026, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s complete unaudited condensed consolidated financial statements an…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 12, 2026, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the three months ended March 31, 2026. The Company also announced that it would conduct a conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s complete unaudited condensed consolidated financial statements and no…
Results of Operations and Financial Condition. On March 19, 2026, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fiscal year ended December 31, 2025. The Company also announced that it would conduct a conference call and audio webcast on Thursday, March 19, 2026, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s complete audited financial statements and notes thereto as of,…
Results of Operations and Financial Condition. On November 13, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the third fiscal quarter ended September 30, 2025. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on Thursday, November 13, 2025, at 4:30 PM EST / 1:30 PM PST, to discuss the update and results. The Company’s…
Results of Operations and Financial Condition. On August 7, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the second fiscal quarter ended June 30, 2025. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on Thursday, August 7, 2025, at 4:30 PM EDT / 1:30 PM PDT, to discuss the update and results. The Company’s complete…
Results of Operations and Financial Condition. On March 27, 2025, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2024. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on Thursday, March 27, 2025, at 4:30 PM EDT / 1:30 PM PDT, to discuss the update and results. The Company’…
Results of Operations and Financial Condition. On March 19, 2024, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2023. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on March 19, 2024, at 4:30 PM EDT/1:30 PM PDT, to discuss the update and results. The Company’s complete a…
Results of Operations and Financial Condition. On November 8, 2023, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its third quarter 2023 financial results. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on November 8, 2023, at 4:30 PM EST/1:30 PM PST, to discuss the update and results. The Company’s complete unaudited financial statements and note…
Results of Operations and Financial Condition. On August 8, 2023, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its second quarter 2023 financial results. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on August 8, 2023, at 4:30 PM EDT/1:30 PM PDT, to discuss the update and results. The Company’s complete unaudited financial statements and notes t…
Results of Operations and Financial Condition. On May 11, 2023, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its first quarter 2023 financial results. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on May 11, 2023, at 4:30 PM EDT/1:30 PM PDT, to discuss the update and results. The Company’s complete unaudited financial statements and notes theret…
Results of Operations and Financial Condition. On March 23, 2023, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its fourth quarter and full-year 2022 financial results. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on March 23, 2023, at 4:30 PM EDT/1:30 PM PDT, to discuss the update and results. The Company’s complete audited financial statements…
Results of Operations and Financial Condition. On November 10, 2022, Relmada Therapeutics, Inc. (“Relmada,” the “Company,” “we,” “us,” “our”)) issued a press release providing a corporate update and reporting its financial results for the three and nine months ended September 30, 2022 . (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on November 10, 2022, at 4:30 PM EST, to discuss the update and results. The…
Results of Operations and Financial Condition. On May 5, 2022, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its first quarter 2022 financial results. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on May 5, 2022, at 4:30 PM EDT, to discuss the update and results. The Company’s complete unaudited condensed financial statements and notes thereto as…
Results of Operations and Financial Condition. On March 23, 2022, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its fourth quarter and full-year 2021 financial results. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on March 23, 2022, at 4:30 PM EDT, to discuss the update and results. The Company’s complete audited financial statements and notes t…
Results of Operations and Financial Condition. On March 23, 2021, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its fourth quarter and full-year 2020 financial results. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on March 23, 2021, at 4:30 PM, to discuss the update and results. A copy of this press release is attached as Exhibit 99.1 to this Cu…